This article is more than 5 years old. Information may no longer be current.

SCORE studies: Triamcinolone a benefit for CRVO but not BRVO

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Michael S. Ip

NEW YORK — In separately conducted studies, triamcinolone therapy proved more efficacious than standard therapy for patients with central retinal vein occlusion but not for patients with branch retinal vein occlusion.

At 1 year, 7% of patients in the observation group of the SCORE-CRVO study had an improvement of 15 ETDRS letters or more compared with 27% of patients treated with 1 mg triamcinolone and 26% treated with 4 mg triamcinolone.

"The 1 mg dose has a safety profile superior to that of the 4 mg group, and the 1 mg dose has a safety profile similar to the observation group," Michael S. Ip, MD, said.

At 12 months in the SCORE-BRVO study, 29% of patients treated with grid laser photocoagulation had a 15 ETDRS letter or better improvement compared with 26% treated with 1 mg triamcinolone and 27% treated with 4 mg triamcinolone, according to Ingrid U. Scott, MD, MPH.

OCT showed reduction in retinal thickness in all three groups, with the greatest benefit seen in the grid laser photocoagulation group. The grid laser photocoagulation group also had a superior safety profile, Dr. Scott said.